140 related articles for article (PubMed ID: 7556391)
1. Antithrombotic effect of a humanized anti-GPIIb/IIIa monoclonal antibody, YM207, in a photochemically induced thrombosis model in monkeys.
Kaku S; Kawasaki T; Sakai Y; Taniuchi Y; Yano S; Suzuki K; Terazaki C; Kawamura K; Masuho Y; Satoh N
Eur J Pharmacol; 1995 Jun; 279(2-3):115-21. PubMed ID: 7556391
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
4. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the antiplatelet agent potential of the whole molecule, F(ab)2 and Fab fragments of humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
Kaku S; Yano S; Kawasaki T; Sakai Y; Suzuki K; Kawamura K; Masuho Y; Satoh N; Takenaka T; Landolfi NF; Co MS
Gen Pharmacol; 1996 Apr; 27(3):435-9. PubMed ID: 8723521
[TBL] [Abstract][Full Text] [Related]
6. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
Shi XL; Shen S; Guo MM; Zhang GJ; Che J; Wang B; Zhou J
Pharmazie; 2015 Dec; 70(12):810-4. PubMed ID: 26817279
[TBL] [Abstract][Full Text] [Related]
7. Prolonged inhibition of acute arterial thrombosis by high dosing of a monoclonal anti-platelet glycoprotein IIb/IIIa antibody in a baboon model.
Kotzé HF; Badenhorst PN; Lamprecht S; Meiring M; Van Wyk V; Nuyts K; Stassen JM; Vermylen J; Deckmyn H
Thromb Haemost; 1995 Aug; 74(2):751-7. PubMed ID: 8585017
[TBL] [Abstract][Full Text] [Related]
8. Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty.
Mazurov AV; Pevzner DV; Antonova OA; Byzova TV; Khaspekova SG; Semenov AV; Vlasik TN; Samko AN; Staroverov II; Ruda MY
Platelets; 2002 Dec; 13(8):465-77. PubMed ID: 12487780
[TBL] [Abstract][Full Text] [Related]
9. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice.
Teng CM; Wu CC; Ko FN; Lee FY; Kuo SC
Eur J Pharmacol; 1997 Feb; 320(2-3):161-6. PubMed ID: 9059849
[TBL] [Abstract][Full Text] [Related]
10. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition.
Huang J; Rebello SS; Faul JD; Lucchesi BR
Pharmacology; 1999 May; 58(5):252-64. PubMed ID: 10087466
[TBL] [Abstract][Full Text] [Related]
11. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
Kawano KI; Hokamura K; Kondo K; Ikeda Y; Suzuki Y; Umemura K
Eur J Pharmacol; 2001 Apr; 417(3):217-22. PubMed ID: 11334853
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
[TBL] [Abstract][Full Text] [Related]
13. [Different inhibiting effects of abciximab and tirofiban on platelet thrombus formation on a collagen surface under flow conditions].
Shimazaki T; Goto S; Sakakibara M; Eto K; Kim JY; Ichikawa N; Yoshida M; Nagaoka Y; Isshiki T; Handa S
J Cardiol; 2000 Aug; 36(2):113-21. PubMed ID: 10955255
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic effect of Z4A5 on coronary thrombosis in a canine model of acute unstable angina.
Jing BB; Li YX; Zhang H; Ren ST; Wang M; Li YP; Shen XL; Wang YL; Zang WJ; Wang B
Br J Pharmacol; 2013 Jun; 169(4):848-59. PubMed ID: 23083032
[TBL] [Abstract][Full Text] [Related]
15. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.
Makkar RR; Litvack F; Eigler NL; Nakamura M; Ivey PA; Forrester JS; Shah PK; Jordan RE; Kaul S
Circulation; 1997 Feb; 95(4):1015-21. PubMed ID: 9054765
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart.
Mickelson JK; Simpson PJ; Lucchesi BR
J Mol Cell Cardiol; 1989 Apr; 21(4):393-405. PubMed ID: 2746660
[TBL] [Abstract][Full Text] [Related]
18. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis.
Kageyama S; Matsushita J; Yamamoto H
Eur J Pharmacol; 2002 May; 443(1-3):143-9. PubMed ID: 12044804
[TBL] [Abstract][Full Text] [Related]
19. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist.
Mousa SA; DeGrado WF; Mu DX; Kapil RP; Lucchesi BR; Reilly TM
Circulation; 1996 Feb; 93(3):537-43. PubMed ID: 8565173
[TBL] [Abstract][Full Text] [Related]
20. Improved Antithrombotic Activity and Diminished Bleeding Side Effect of a PEGylated α
Kuo YJ; Chang YT; Chung CH; Chuang WJ; Huang TF
Toxins (Basel); 2020 Jun; 12(7):. PubMed ID: 32605221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
